about
Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case.Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option.Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia.Heterogeneity among splanchnic vein thrombosis associated with myeloproliferative neoplasms.Nilotinib induced Bone Marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia.Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patientsLymphocytic variant hypereosinophilia: a challenging diagnosis of a rare disease with pleomorphic clinical pictureBlast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic OptionsSafety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II studyImpact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC groupDefective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasmsSecond primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patientsSplanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 casesA randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemiaSecond cancers in MPN: Survival analysis from an international studyNilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatmentHow many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study)Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control studyProspective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML studyIntegrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approachUGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemiaItalian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiativeDigital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuationImpact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinibReply to "COVID-19 in persons with haematological cancers": a focus on myeloid neoplasms and risk factors for mortalityLow-Dose Ponatinib Is A Good Option In Chronic Myeloid Leukemia Patients Intolerant To Previous Tkis
P50
Q41613498-B01E14C0-7C48-4088-961A-23440D5F437BQ47877989-FB97A172-9C22-431A-A5D6-EF2D2C0851D7Q48179206-E31BD5A9-8F32-455E-AC45-D989E8E90789Q48213317-D9AC49EA-87E0-4E9F-8226-934AC44FD4EDQ51732265-3AFA3227-5FF4-4CD4-A234-142944792B6EQ52720420-1E412E3B-8720-470E-BE65-330AAF5C18AFQ54035197-4660DA21-2A9C-4702-8D14-0D9EE07D31D3Q54977711-23201758-C0D6-4CDE-8916-89EF9264E677Q56365273-15808CD2-F3D0-43FA-991F-42C20B706A87Q64043758-1D4CDFA1-8319-4BFA-8BF4-5C4FB8DC4A63Q64250444-2C7AE972-E909-4EE1-B77A-DE36A29B0897Q89665051-79CE1A31-0605-4F03-8549-31C68D96802FQ90541890-3B951920-F718-4557-B6FB-6DA9ED311304Q91164948-FC55FE94-CB53-46C1-B039-89AC79F095A0Q91167221-2FEA4962-1AE2-4545-B596-A7DCC796B799Q91265956-F1FDD73A-88B3-4F45-AF96-78E288852DE3Q91715030-24C926CD-204E-4B9C-8C8D-D9026F3A58F1Q91801892-E7399DBF-12B2-429B-990E-6004D31BF5C4Q91989455-C87B55FC-EE46-4346-AC0E-2F68F6C9A734Q92143253-E2BBD26A-7105-4C01-9655-A0CB313528ADQ92149183-57902995-3A1D-4144-9D02-A1BDA22EBA44Q92206129-BF41894D-5198-4047-97B1-D4F0F4263670Q92252507-054A51E4-6F67-4C77-9263-4A7A42BF0482Q92270548-BAF09104-6D02-4588-85F6-590FC17C40B8Q92303595-97704182-9CA6-4192-9D91-15F0985B10D1Q92622295-F49B0D77-3C8C-427D-B1BB-CF6C3390ECC5Q92868956-45066DF9-02F8-4B0D-8316-9ABF1312936BQ93091989-0EC29614-70E7-4D63-BA41-313101BD2FBEQ95840066-60D97841-1669-4F9C-80CE-B3F4860B4D9AQ96584997-F7E46B37-AA16-4D91-B155-708487CDA454
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alessandra Iurlo
@ast
Alessandra Iurlo
@en
Alessandra Iurlo
@es
Alessandra Iurlo
@nl
type
label
Alessandra Iurlo
@ast
Alessandra Iurlo
@en
Alessandra Iurlo
@es
Alessandra Iurlo
@nl
prefLabel
Alessandra Iurlo
@ast
Alessandra Iurlo
@en
Alessandra Iurlo
@es
Alessandra Iurlo
@nl
P106
P21
P31
P496
0000-0002-4401-0812